

PRECISION TACE™

DC Bead™


Drug Delivery Embolisation System
for **PRECISION TACE™**

Specifically designed
to be loaded with
doxorubicin,
DC Bead™ brings a
new level of efficacy,
accuracy and
convenience to trans-arterial
chemo-embolisation:

PRECISION TACE

Less


Lower dose of doxorubicin
in the system¹



PRECISION
TACE:
3 days
post-treatment²

More


Higher dose of doxorubicin
in the tumour for longer^{2,3}




PRECISION
TACE:
14 days
post-treatment²

Every Time

A consistent product for a
consistent treatment³



1. Poon, R., Treatment of Asian Patients with Hepatocellular Carcinoma (HCC) using doxorubicin Eluting Bead Embolization (PRECISION ASIA STUDY). Presentation at CIRSE 2004.
2. Geschwind, J., New Intraarterial Drug Delivery System for Liver Cancer: Presentation RSNA 2004 and ASCO 2005.
3. Internal data on file. Biocompatibles UK Ltd.



Less

More Every Time


Drug Delivery
Embolisation System for

PRECISION TACE™

Less – Lower dose of doxorubicin
in the system^{1,2}

- Compared to conventional TACE, PRECISION TACE reduces the peak systemic blood plasma levels by more than 99%.²
- Complication rates are reduced to 7% at six months³ compared to 27.5% reported with conventional TACE.⁴
- High plasma levels of chemotherapeutic drugs, like doxorubicin, are often associated with toxicity related complications.


Systemic doxorubicin exposure
Pharmacokinetic evaluation



“The Drug Eluting Bead is a promising option. Our patients have tolerated the treatment well”.

Dr Ronnie Poon, Queen Mary Hospital, Hong Kong

Less More Every Time



Drug Delivery Embolisation System for

PRECISION TACE

DC Bead™ hydrogel microspheres are intended to be loaded with doxorubicin for the purpose of:

- Embolisation of vessels supplying malignant hypervascularised tumour(s).
- Delivery of a local, controlled, sustained dose of doxorubicin to the tumour(s).

Label Colour	Nominal Bead Size	Volume of Beads	Product Code
Yellow	100 - 300 µm	2ml	DC2V103
Blue	300 - 500 µm	2ml	DC2V305
Red	500 - 700 µm	2ml	DC2V507
Green	700 - 900 µm	2ml	DC2V709

10ml glass vial. Each vial contains approximately 2ml of DC Bead™ in non-pyrogenic, sterile, physiological buffered saline. Total volume of saline and DC Bead™ is approximately 8ml. The vial is stopper sealed by an aluminium cap equipped with a colour-coded lid.


Manufactured under ISO13485, ISO9001 quality systems.

Biocompatibles UK Limited
Chapman House
Farnham Business Park
Weydon Lane
Farnham
Surrey GU9 8QL
United Kingdom
Tel: +44 (0) 1252 732 732
Fax: +44 (0) 1252 732 777
www.biocompatibles.com

DC Bead™ is a trademark of Biocompatibles UK Ltd
PRECISION TACE™ is a trademark of Biocompatibles UK Ltd
EC308/2 © 2006 Biocompatibles UK Ltd

References

1. Varela, M., Real, M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads reduces the systemic availability of doxorubicin. A pharmacokinetic assessment. Poster presentation. AASLD 2005.
2. Poon, R., Treatment of Asian Patients with Hepatocellular Carcinoma (HCC) using doxorubicin Eluting Bead Embolization (PRECISION ASIA STUDY) Presentation at CIRSE 2004.
3. Internal data on file. Biocompatibles UK Ltd.
4. Llovet J.M., et al. The Lancet 359:1734-1739; 2002.
5. Johnson et al. J. Hepatology 1991; 13:120-127.




Less **More** Every Time

Drug Delivery
Embolisation System for

PRECISION TACE™

More – Higher dose of doxorubicin
in the tumour for longer^{1,2}


- PRECISION TACE tumour response rates are 78% at six months post procedure¹, significantly higher than the tumour response rate of 35% observed with conventional TACE.³
- PRECISION TACE tumour response rates are 87% at six months post procedure when patients were treated at the maximum dose available (150mgs).¹



“Chemo-embolisation using drug eluting beads facilitates a predictable bioavailability of doxorubicin with marked reduction of systemic exposure. While maintaining the local antitumoural efficacy, this favourable profile should result in a better tolerance to treatment with reduction of drug related toxicity, even if increasing the dosage beyond the usual maximum tolerated dose”.

M Varela et al, Barcelona Liver Cancer Group, University of Barcelona, Spain

Less **More** Every Time



Drug Delivery Embolisation System for

PRECISION TACE

DC Bead™ hydrogel microspheres are intended to be loaded with doxorubicin for the purpose of:

- Embolisation of vessels supplying malignant hypervascularised tumour(s).
- Delivery of a local, controlled, sustained dose of doxorubicin to the tumour(s).

Label Colour	Nominal Bead Size	Volume of Beads	Product Code
Yellow	100 - 300 µm	2ml	DC2V103
Blue	300 - 500 µm	2ml	DC2V305
Red	500 - 700 µm	2ml	DC2V507
Green	700 - 900 µm	2ml	DC2V709

10ml glass vial. Each vial contains approximately 2ml of DC Bead™ in non-pyrogenic, sterile, physiological buffered saline. Total volume of saline and DC Bead™ is approximately 8ml. The vial is stopper sealed by an aluminium cap equipped with a colour-coded lid.


Manufactured under ISO13485, ISO9001 quality systems.

Biocompatibles UK Limited
Chapman House
Farnham Business Park
Weydon Lane
Farnham
Surrey GU9 8QL
United Kingdom
Tel: +44 (0) 1252 732 732
Fax: +44 (0) 1252 732 777
www.biocompatibles.com

DC Bead™ is a trademark of Biocompatibles UK Ltd
PRECISION TACE™ is a trademark of Biocompatibles UK Ltd
EC309/2 © 2006 Biocompatibles UK Ltd

References

1. Internal data on file. Biocompatibles UK Ltd.
2. Poon, R., Treatment of Asian Patients with Hepatocellular Carcinoma (HCC) using doxorubicin Eluting Bead Embolization (PRECISION ASIA STUDY). Presentation at CIRSE 2004.
3. Llovet J.M., et al. The Lancet 359; 1734-1739; 2002.



Less More **Every Time**


Drug Delivery
Embolisation System for

PRECISION TACE™


Every time – A consistent product for a consistent treatment¹

- A consistent product for a consistent treatment.
- Proven dosing and elution of doxorubicin.
- Calibrated microspheres for precise targeting of the tumour.


In vitro doxorubicin elution
PRECISION TACE vs. TACE¹



Predictable doxorubicin elution
PRECISION TACE¹



Less More **Every
Time**



Drug Delivery Embolisation System for

PRECISION TACE

DC Bead™ hydrogel microspheres are intended to be loaded with doxorubicin for the purpose of:

- Embolisation of vessels supplying malignant hypervascularised tumour(s).
- Delivery of a local, controlled, sustained dose of doxorubicin to the tumour(s).

Label Colour	Nominal Bead Size	Volume of Beads	Product Code
Yellow	100 - 300 µm	2ml	DC2V103
Blue	300 - 500 µm	2ml	DC2V305
Red	500 - 700 µm	2ml	DC2V507
Green	700 - 900 µm	2ml	DC2V709

10ml glass vial. Each vial contains approximately 2ml of DC Bead™ in non-pyrogenic, sterile, physiological buffered saline. Total volume of saline and DC Bead™ is approximately 8ml. The vial is stopper sealed by an aluminium cap equipped with a colour-coded lid.

Manufactured under ISO13485, ISO9001 quality systems.

Biocompatibles UK Limited
Chapman House
Farnham Business Park
Weydon Lane
Farnham
Surrey GU9 8QL
United Kingdom
Tel: +44 (0) 1252 732 732
Fax: +44 (0) 1252 732 777
www.biocompatibles.com

DC Bead™ is a trademark of Biocompatibles UK Ltd
PRECISION TACE™ is a trademark of Biocompatibles UK Ltd
EC310/2 © 2006 Biocompatibles UK Ltd

Reference

1. Internal data on file. Biocompatibles UK Ltd.